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COST-EFFECTIVENESS ANALYSIS OF ORAL
PHARMACOLOGICAL TREATMENTS OF ERECTILE
DYSFUNCTION
Roy S, Roy AN, Miller LA
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To make a comparative cost-effectiveness analy-
sis for treatment strategies involving PDE-5 inhibitors—silde-
naﬁl, tadalaﬁl, vardenaﬁl, or placebo (no treatment) among 
men 60 years or older suffering from erectile dysfunction.
METHODS: A Markov decision-analytic model was used to
examine cost-effectiveness. The model was run for two lengths
of time—lifetime (up to 100 years of age—by when all patients
died) and up to 80 years of age (by when all men discontinued
sexual intercourse). Markov states were deﬁned as—disease, no
disease (cured), morbid (from treatment) and dead (absorbing
state). Transition probabilities between states were derived from
clinical trials reported in the literature. Costs were assigned from
a societal perspective using a combination of published estimates
and federal standards. Direct costs of treatment were calculated
based on Average Wholesale price of the most common strength
of each drug used for 1.5 attempts at sexual intercourse per week
on an average. Effectiveness was measured in Quality Adjusted
Life Years (QALYs) using utility values assigned to each Markov
state—also collected from published studies. One-way sensitiv-
ity analyses were performed on effectiveness, cost and utility
variables to test robustness of the results. RESULTS: Tadalaﬁl
treatment was found to dominate all other strategies (including
no treatment) in both scenarios. Tadalaﬁl-treated men gain more
QALYs than any other strategy at costs less than the cost of other
treatment and allied morbidity-related costs. Results remained
mostly unchanged in the lifetime scenario after sensitivity analy-
ses. ‘No treatment’ was found to be a better option if there were
no long-term costs involved with managing treatment related
morbidity. Vardenaﬁl emerged as a better option at thresholds 
of 66.65% effectiveness for tadalaﬁl or at 73.54% effectiveness
for vardenaﬁl. CONCLUSIONS: For men suffering from ED,
tadalaﬁl use could be more cost-effective than other oral agents
or no treatment.
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OBJECTIVES: Abnormal uterine bleeding (AUB) is a common
gynecological disorder that affects 10%–30% of women of
reproductive age, yet the overall economic burden of AUB on
society is largely unknown. The purpose of this study is to quan-
tify this burden from a societal perspective. METHODS: We
conducted a systematic literature review of PubMed for English-
language studies published from 1980 to 2005. Outcomes of
interest included health care utilization, direct treatment cost,
and work productivity loss due to absenteeism and presenteeism
(ie, indirect cost) attributable to AUB. The direct treatment cost
for AUB includes costs for physician visits, medical therapy, 
minimally invasive surgery (endometrial ablation), and major
surgery (hysterectomy). Using information on disease prevalence,
treatment utilization, direct treatment cost per procedure/
episode, and indirect cost, we conservatively estimated the eco-
nomic burden of AUB from a societal perspective. RESULTS: We
identiﬁed 6 studies on the prevalence of AUB and 30 studies on
health care utilization. One study evaluated indirect cost due to
absenteeism but no study focused on productivity loss due to 
presenteeism. Assuming that the prevalence rate of AUB is 10%
and that one-quarter of AUB patients seek medical care, it is esti-
mated that the total direct treatment cost attributable to AUB
was $1 billion annually. Hysterectomy accounted for more than
half of this cost. The estimated indirect cost was substantially
larger, amounting to approximately $12 billion per year. CON-
CLUSIONS: AUB imposes a tremendous economic burden on
society, with direct and indirect costs adding up to approximately
$13 billion per year. Because studies on presenteeism are cur-
rently lacking, the full economic impact of AUB is likely to be
underestimated. Further research that quantiﬁes this missing
component of overall cost will help to better estimate the burden
of AUB and to guide future health resource allocation and clin-
ical decision making.
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A SYSTEMATIC REVIEW OF ATROPHIC VAGINITIS
TREATMENT, DURATION OF THERAPY,AND HEALTH 
CARE COSTS
Balu S1, Joshi AV2, Cobden D2, Lee WC1, Pashos CL1
1Abt Associates Inc, Lexington, MA, USA, 2Novo Nordisk Inc,
Princeton, NJ, USA
OBJECTIVES: A systematic review of the prevalence of atrophic
vaginitis, treatments involved, therapy duration, and associated
healthcare costs was undertaken to identify studies with clinical
and economic relevance and gaps in literature. METHODS: A
systematic literature search using an exhaustive list of relevant
search terms (1990–2004) was performed to identify articles
with qualitative and quantitative data on atrophic vaginitis treat-
ments, treatment duration, and economic impact of treatment
duration. Electronic Medline® and PubMed® searches along
with manual review of bibliographies were conducted in differ-
ent phases for article retrieval. RESULTS: Out of 35 retrieved
studies, 6 were on epidemiology, 14 on treatment patterns, 8 on
treatment duration, and 7 studies showed comparisons between
vaginal tablets and other vaginal preparations. Overall, studies
examining prevalence showed that atrophic vaginitis was com-
monly occurring among postmenopausal women (10–40%), 
and affecting as many as 15% of pre-menopausal women and
10–25% of women on systemic hormone therapy. Diagnosis of
this condition was low with less than 25% discussing the con-
dition with their healthcare providers and only 20–25% seeking
medical attention. Treatment duration was found to be in the
range of 2–12 months (weighted average of 4.1 months). Studies
on long-term safety and efﬁcacy of treatment are lacking. Vaginal
tablets were preferred over vaginal creams due to convenience
and ease of administration. CONCLUSIONS: No data exist that
mirror treatment duration in a “real-world” setting. There is a
complete lack of studies correlating treatment duration with
overall health care costs both at an individual and national level.
Health economic studies examining resource utilization patterns,
cost drivers and economic burden of this condition on individu-
als and society at large were not found. Future research needs to
examine relationships between treatment duration, choice of
medication, adherence, incidence of adverse events, and resource
use and costs.
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MEDICAL RESOURCE UTILIZATION IN DIAGNOSED
PREMATURE EJACULATION PATIENTS
Nuyts G1, Hill K1, Jamieson C2
1Johnson and Johnson, Raritan, NJ, USA, 2Johnson and Johnson,
Mountain View, CA, USA
OBJECTIVES: Estimates show >20% of men are affected by pre-
mature ejaculation, yet very few seek health care and are diag-
nosed by a physician. This retrospective study of US medical
